Personalised Multidisciplinary Treatment in Moderate to Severe IBS
Key facts
- Who runs it
- Linkoeping University
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people enrolled
- Started
- 23 Sept 2021
- Ended
- 15 Jun 2026
- Type of study
- InterventionalOne group gets an existing treatment, for comparison.
- Treatments tested
- Physician-module
- Dietician module
- Psychologist module
- Physiotherapy module
- Record updated
- 16 April 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- IBS diagnosis confirmed according to the Rome IV criteria
- Moderate-to-severe symptoms based on the IBS Symptom Severity Score (IBS-SSS)
- Age 18-65 years
- Written informed consent
Who cannot take part
- Contraindications to MRI, e.g., claustrophobia, pregnancy, or metallic implants
- History of major gastrointestinal surgery, e.g., appendectomy
- Severe psychiatric illness, such as bipolar disorder or schizophrenia
- Insufficient Swedish language knowledge to complete the questionnaires
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a 12-month longitudinal intervention study in adults (18-65 years) with moderate-severe IBS (IBS-SSS ≥175) evaluating a personalized, patient-centered multidisciplinary treatment delivered in a Swedish tertiary care setting. The program includes an internet-based IBS school followed by four evidence-based modules (physician-led medical management/education, dietician-led dietary intervention, psychologist-led IBS-focused behavioral therapy, and physiotherapy) delivered in a sequence chosen by the participant, with symptom evaluation after each module. Outcomes are assessed before and after treatment, with the primary endpoint defined as treatment response (IBS-SSS reduction ≥50 points), and secondary endpoints covering symptom/psychological measures, visceral sensitivity and biological stress plus gut biomarkers, and multimodal brain imaging (structural MRI, rs-fMRI, task fMRI, and insula MRS).
The group in the trial
- Multidisciplinary multimodal intervention (IBS)Existing treatment, for comparison
Single-arm intervention: all participants are assigned to a multimodal, multidisciplinary IBS treatment program delivered by a multidisciplinary team. No control group was included due to the nature of the study.
Treatment: Physician-module, Dietician module, Psychologist module, and Physiotherapy module
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Personalised Multidisciplinary Multimodal Treatment in IBS
- Record updated
- 16 April 2026